ASP-0739 by Astellas Pharma for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

ASP-0739 is under clinical development by Astellas Pharma and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ASP-0739’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ASP-0739 overview

ASP-0739 is under development for the treatment of solid tumors including relapsed/refractory (R/R) synovial sarcoma (SS) or myxoid/round cell liposarcoma, melanoma, non-small cell lung cancer [NSCLC]-adenocarcinoma and squamous cell, and esophageal squamous cell carcinoma. The therapeutic candidate consists of tumor antigen loaded artificial adjuvant vector cells. It acts by targeting cells expressing cancer-testis antigen.

Astellas Pharma overview

Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

For a complete picture of ASP-0739’s drug-specific PTSR and LoA scores, buy the report here.